{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:07:43Z","timestamp":1773338863512,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.vaccine.2025.127562","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T06:15:13Z","timestamp":1754374513000},"page":"127562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 open-label trial"],"prefix":"10.1016","volume":"62","author":[{"given":"Kenji","family":"Kuriyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenkichi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Sakui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron P.","family":"Schuring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127562_bb0005","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.7861\/clinmed.2020-0896","article-title":"Autonomic dysfunction in \u2018long COVID\u2019: rationale, physiology and management strategies","volume":"21","author":"Dani","year":"2021","journal-title":"Clin Med"},{"key":"10.1016\/j.vaccine.2025.127562_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-048391","article-title":"Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study","volume":"11","author":"Dennis","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2025.127562_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0267392","article-title":"Comprehensive clinical assessment identifies specific neurocognitive deficits in working-age patients with long-COVID","volume":"17","author":"Holdsworth","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127562_bb0020","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.vaccine.2025.127562_bb0025","author":"World Health Organization (WHO)"},{"key":"10.1016\/j.vaccine.2025.127562_bb0030","author":"World Health Organization (WHO)"},{"key":"10.1016\/j.vaccine.2025.127562_bb0035","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jiph.2024.02.016","article-title":"Durability of COVID-19 humoral immunity post infection and different SARS-COV-2 vaccines","volume":"17","author":"Alroqi","year":"2024","journal-title":"J Infect Public Heal"},{"key":"10.1016\/j.vaccine.2025.127562_bb0040","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167955","article-title":"Durability of immune responses to mRNA booster vaccination against COVID-19","volume":"133","author":"Arunachalam","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2025.127562_bb0045","doi-asserted-by":"crossref","first-page":"21232","DOI":"10.1038\/s41598-022-25134-0","article-title":"Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex","volume":"12","author":"Korosec","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127562_bb0050","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127562_bb0055","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 COVID-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127562_bb0060","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1016\/j.vaccine.2023.05.051","article-title":"Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373","volume":"41","author":"Alves","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127562_bb0065","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1016\/j.vaccine.2023.05.001","article-title":"Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: primary analysis report of a phase 3 open-label trial","volume":"41","author":"Kuriyama","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127562_bb0070","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S1473-3099(22)00420-0","article-title":"Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial","volume":"22","author":"Mallory","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127562_bb0075","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127562_bb0080","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJMc2215509","article-title":"Immunogenicity of a fourth homologous dose of NVX-CoV2373","volume":"388","author":"Alves","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127562_bb0085","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/s41598-023-27698-x","article-title":"Novavax NVX-COV2373 triggers neutralization of omicron sub-lineages","volume":"13","author":"Bhiman","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127562_bb0090","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.vaccine.2023.12.036","article-title":"Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: interim analysis report of a phase 3 open-label trial","volume":"42","author":"Kuriyama","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127562_bb0095","author":"Pharmaceuticals and Medical Devices Agency (PMDA)"},{"key":"10.1016\/j.vaccine.2025.127562_bb0100","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1016\/j.vaccine.2022.04.035","article-title":"Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: interim report of a phase I\/II randomized controlled trial","volume":"40","author":"Masuda","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127562_bb0105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41467-022-35768-3","article-title":"Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial","volume":"14","author":"Fong","year":"2023","journal-title":"Nat Commun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500859X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500859X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T03:25:15Z","timestamp":1766546715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2500859X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":21,"alternative-id":["S0264410X2500859X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127562","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 open-label trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Takeda Pharmaceutical Company Limited. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127562"}}